MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-11-2023
vTv Therapeutics Operating Expenses 2011-2026 | VTVT
Annual Operating Expenses vTv Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.6 M | 25.7 M | 18.3 M | 23.7 M | 32.3 M | 51 M | 55.7 M | 38.7 M | 30.4 M | 36.8 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 55.7 M | 18.3 M | 33.7 M |
Quarterly Operating Expenses vTv Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 M | 7.43 M | - | 5.69 M | 4.04 M | 8.48 M | - | 4.6 M | 4.68 M | 5.27 M | - | 2.84 M | 4.2 M | 6.65 M | - | 5.43 M | 6.62 M | 5.21 M | - | 4.86 M | 11.3 M | 11.2 M | - | 11.6 M | 12.6 M | 13.8 M | - | 13.6 M | 14.8 M | 13.9 M | - | 9.57 M | 8 M | 9.77 M | - | 5.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.8 M | 2.84 M | 8.15 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.6 | 1.34 % | $ 8.66 B |  Australia |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.66 | - | $ 16.7 M |  USA |
 |
BioNTech SE
BNTX
|
512 M | $ 91.28 | - | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Burford Capital Limited
BUR
|
106 M | $ 4.48 | - | $ 736 M |  Britain |
 |
Cerus Corporation
CERS
|
149 M | $ 1.85 | - | $ 353 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.67 | - | $ 196 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 31.37 | - | $ 2.08 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
8.73 M | $ 0.44 | - | $ 5.04 M |  Israel |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
16 M | $ 2.32 | - | $ 1.03 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Catalyst Pharmaceuticals
CPRX
|
206 M | $ 24.98 | - | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
85.3 M | $ 10.14 | - | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
49.6 M | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
33.9 M | $ 0.53 | - | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
173 M | $ 37.7 | - | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
668 M | $ 49.15 | - | $ 4.42 B |  Schweiz |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
CytomX Therapeutics
CTMX
|
98.6 M | $ 4.4 | - | $ 607 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
42 M | $ 0.86 | - | $ 5.79 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Cue Biopharma
CUE
|
54 M | $ 0.18 | - | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
153 M | $ 20.36 | - | $ 2.84 B | France |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Denali Therapeutics
DNLI
|
502 M | $ 19.38 | - | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
10.1 M | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
17.3 M | $ 3.54 | - | $ 238 B | Britain |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Entera Bio Ltd.
ENTX
|
11.3 M | $ 1.19 | - | $ 55.5 M | Israel |
 |
Equillium
EQ
|
23.6 M | $ 2.01 | - | $ 115 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.13 B | $ 330.34 | - | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Fate Therapeutics
FATE
|
154 M | $ 1.19 | - | $ 141 M | USA |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |